Imunon earnings release, August 11, 2026

Imunon, Inc. (IMNN) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

IMUNON

Reports Second Quarter 2026 Financial Results and Provides Business Update

IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by the first half of 2029, supported by strong Phase 2 clinical data showing significant overall survival benefit

Company to hold conference call today at 11:00 a.m. EDT

LAWRENCEVILLE,

N.J., August 11, 2026 – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three months and six months ended June 30, 2026, and highlighted recent business updates including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.

“The second quarter brought continued momentum for IMNN-001,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON.

“Enrollment in our pivotal Phase 3 OVATION 3 study continues to exceed our planning assumptions, reflecting the compelling survival data generated in OVATION 2, our highly favorable safety profile, and growing confidence among investigators in IMNN-001’s potential to improve outcomes for women with newly diagnosed advanced ovarian cancer.”

“We were also encouraged by new preliminary data from our ongoing Phase 2 minimal residual disease

(MRD) study, which showed a deeper antitumor response in patients treated with IMNN-001, including higher rates of circulating tumor DNA clearance and no evidence of disease following frontline therapy. We believe these findings provide further independent evidence of IMNN-001’s biological activity and reinforce the mechanism underlying the survival benefit observed in the

OVATION 2 study, while we remain fully focused on our highest priority of efficiently advancing OVATION 3. Based on the data generated to date, we believe IMNN-001 has the potential to become the first frontline immunotherapy to meaningfully improve overall survival in advanced ovarian cancer and establish a new standard of care for women facing this disease.”

RECENT

DEVELOPMENTS

IMNN-001

Corporate

Development:

Upcoming

Events:

FINANCIAL

RESULTS FOR THE SECOND QUARTER 2026

Net loss for the second quarter of 2026 was $2.8 million, or $0.54 per share, compared with a net loss of $2.7 million, or $2.15 per share, for the second quarter of 2025. Operating expenses were $2.8 million for each of the second quarters of 2026 and 2025.

Research and development expenses increased to $1.5 million in the second quarter of 2026 compared to $1.2 million in the same period of 2025.

During 2025, the Company initiated enrollment in the OVATION 3 Study and in 2026 closed out the OVATION 2 Study.

General and administrative expenses decreased to $1.3 million in the second quarter of 2026 compared to $1.5 million in the same period of 2025.

FINANCIAL

RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026

Net loss for the first half of 2026 was $7.1 million, or $1.38 per share, compared with a net loss of $6.8 million, or $6.08 per share, for the same period of 2025. Operating expenses were $7.1 million for the first half of 2026 compared to $6.9 million for the same period of 2025.

Research and development expenses increased to $3.8 million in the first half of 2026 compared to $3.4 million in the same period of 2025. During

2025, the Company initiated enrollment in the OVATION 3 Study and in 2026 closed out the OVATION 2 Study.

General and administrative expenses decreased to $3.3 million in the first half of 2026 compared to $3.5 million in the same period of 2025.

Net cash used for operating activities was $7.0 million for the first half of 2026, compared with $5.8 million for the same period last year.

This increase was primarily due to trial-related expenses associated with the OVATION 3 trial. As of June 30, 2026, cash and cash equivalents were $6.9 million.

Conference

Call and Webcast

The

Company will be hosting a conference call to review second quarter 2026 financial results and provide a business update today, August 11, 2026, at 11:00 a.m. EDT. To participate in the call, please dial (800) 715-9871 (U.S. and Canada/Toll Free) or (646) 307-1963 (U.S./Toll) and ask for the IMUNON Second Quarter 2026 Financial Results Call (Conference ID 8021948). A live webcast of the call will also be available here.

An audio replay of the call will be available for 90 days and can be accessed at (800) 770-2030 (U.S. and Canada/Toll Free) or (609) 800-9909

(U.S./Toll) using replay access code 8021948#.

About

IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The

Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical... (truncated)quarter of 2025. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended June 30, — (in thousands except per share amounts)

Three Months Ended June 30, – 2025Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating expenses:Research and development1,4651,2273,8023,392
Operating expenses:General and administrative1,3271,5413,2963,521
Operating expenses:Total operating expenses2,7922,7687,0986,913
Operating expenses:Loss from operations-2,792-2,768-7,098-6,913
Other (expense) income:Other income(loss), net-22273570
Other (expense) income:Net loss-2,814-2,741-7,063-6,843
Net loss per common shareBasic and diluted-0.54-2.15-1.38-6.08
Weighted average shares outstandingBasic and diluted5,2331,2775,1341,124

Balance Sheet

June 30, 2026 — (in thousands)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents6,8648,781
Current assetsAdvances, deposits on clinical programs and other current assets1,8271,943
Current assetsTotal current assets8,69110,724
Current assetsProperty and equipment459530
Other assetsRestricted Cash5,000
Other assetsOperating lease right-of-use assets789984
Other assetsDeposits and other assets5050
Other assetsTotal other assets5,8391,034
Other assetsTotal assets14,98912,288
Current liabilitiesAccounts payable and accrued liabilities2,8474,218
Current liabilitiesNote payable – current portion Note A1,500
Current liabilitiesOperating lease liability – current portion432406
Current liabilitiesTotal current liabilities4,7794,624
Current liabilitiesNote Payable – Note A673
Current liabilitiesNote Payable – Note B4,861
Current liabilitiesOperating lease liability – noncurrent portion379602
Current liabilitiesDerivative liability108
Current liabilitiesTotal liabilities10,8005,226
Stockholders’ equityPreferred stock, including additional paid-in capital2,252
Stockholders’ equityCommon stock4734
Stockholders’ equityAdditional paid-in capital430,336428,411
Stockholders’ equityAccumulated deficit-428,631-421,298
Stockholders’ equity4,2747,147
Stockholders’ equityLess: Treasury stock-85-85
Stockholders’ equityTotal stockholders’ equity4,1897,062
Stockholders’ equityTotal liabilities and stockholders’ equity14,98912,288
Full release

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,”

“will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), and include statements regarding our planned stock split. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor

Contact:

Valter

Pinto

KCSA

Strategic Communications

212-896-1254 imunon@kcsa.com

(Tables to Follow)

IMUNON,

Inc.

Condensed

Consolidated Statements of Operations

(in thousands except per share amounts)

IMUNON, Inc.

Selected Balance Sheet Information

(in thousands)

#

# #

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.